JournalsHub
.online
Find My Journal
SC

Sant P. Chawla

Sarcoma Oncology Center US

ORCID 0000-0002-9522-6744
557
Publications
18,944
Citations
63
H-Index
170
i10-Index
0.49
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial OA
Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla, Dong‐Wan Kim, B. Bui-Nguyen +18 more
The Lancet 2012
2,057
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials OA
Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, Salvatore Siena, Alice T. Shaw +33 more
The Lancet Oncology 2019
1,700
The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
Paul J. Hesketh, Steven M. Grunberg, Richard J. Gralla, David Warr, Fausto Roila +9 more
Journal of Clinical Oncology 2003
770
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial OA
Patrick Schöffski, Sant P. Chawla, Robert G. Maki, Antoîne Italiano, Hans Gelderblom +13 more
The Lancet 2016
755
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
David M. Thomas, Robert M. Henshaw, Keith M. Skubitz, Sant P. Chawla, Arthur P. Staddon +7 more
The Lancet Oncology 2010
706

Publications

555 total

1311 Targeting TGF-β RI signaling with the novel vactosertib: preliminary antitumor activity in a phase 1 study in patients with recurrent, refractory, and progressive osteosarcoma

Jun Ah Lee, Kristen VanHeyst, W. Cho, Brian AVan Tine, Sant P. Chawla - Late-Breaking Abstracts, 2025
Cited by 0 Semantic Scholar

THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN CHONDROSARCOMA: RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY

Robin L. Jones, V. Wang, Mark Doherty, Ana Sebio García, S. Stacchiotti - ESMO Rare Cancers, 2025
Cited by 2 Semantic Scholar

Detecting hotspots of intra- and transchromosomal fusions in liposarcomas by RNA sequencing.

Dmitrii Grachev, Danil Ivanov, O. Baranov, V. Kushnarev, Melissa Clemons - Journal of Clinical Oncology, 2025
Cited by 0 Semantic Scholar

548 A Phase 1/2 study of a first-in-class non-cellular antibody-drug conjugate, micvotabart pelidotin (micvo), in combination with pembrolizumab in advanced head & neck squamous cell carcinoma (HNSCC)

G. J. Hanna, F. Johnson, D. Zandberg, G. Rabinowits, N. Choudhury - Regular and Young Investigator Award Abstracts, 2025
Cited by 0 Semantic Scholar

170 Identifying novel targets for antibody-drug conjugates in sarcomas using RNA sequencing OA

V. Kushnarev, A.E. Shevkoplias, K. Kryukov, A. Bagaev, Jochen K. Lennerz - Regular and Young Investigator Award Abstracts, 2024
Cited by 0 Semantic Scholar

183 Comprehensive molecular profiling in the management of patients with diverse sarcoma subtypes OA

Artem Tarasov, V. Kushnarev, Angelina Khachatryan, K. Kryukov, A. Novokreshchenova - Regular and Young Investigator Award Abstracts, 2024
Cited by 0 Semantic Scholar

TP013/#1585  Sb221: a proof-of-concept study to assess the combination of SON-1010 (IL12-FHAB) and atezolizumab in patients with platinum-resistant ovarian cancer (PROC): trial in progress

R. Wenham, Bo Gao, Carolyn L. Bampton, Brett Hamilton, J. Chern - E-Poster Viewing Abstracts – Trials in Progress, 2024
Cited by 0 Semantic Scholar

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse, Víctor Moreno, Rafael López‐López et al. - The Lancet Oncology, 2020
Cited by 443 OpenAlex

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

Michael C. Heinrich, Robin L. Jones, Margaret von Mehren, Patrick Schöffski, César Serrano et al. - The Lancet Oncology, 2020
Cited by 300 OpenAlex

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials PDF

Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, Salvatore Siena, Alice T. Shaw et al. - The Lancet Oncology, 2019
Cited by 1,700 OpenAlex

Research Topics

Sarcoma Diagnosis and Treatment (218) Cancer Research and Treatments (74) Vascular Tumors and Angiosarcomas (61) Lung Cancer Treatments and Mutations (56) CAR-T cell therapy research (51)

Frequent Co-Authors

JE
Jean‐Yves Blay
7 joint publications
SC
Scott M. Schuetze
5 joint publications
PA
Patrick Schöffski
4 joint publications
AX
Axel Le Cesne
4 joint publications
AR
Arthur P. Staddon
3 joint publications
HA
Hans Gelderblom
3 joint publications

Affiliations

Université Claude Bernard Lyon 1
FR 2017 - 2012
University of Southern California
US 2012 - 1999
Santa Monica College
US 2025 - 2011
University of Maryland, Baltimore
US 2009 - 2009
Cedars-Sinai Medical Center
US 2013 - 1989

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now